Search is Powered by Google
Cancer / Oncology News

Elekta Announces Availability Of Elekta Infinity With VMAT Technology For Fast, More Precise Treatment Of Cancer

Main Category: Cancer / Oncology
Article Date: 22 Sep 2008 - 2:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:5 stars

5 (1 votes)

Article Opinions: 0 posts

Elekta, pioneering significant innovations and clinical solutions for cancer and neurological conditions, announced new product offerings from the Elekta Group. Topping the list of innovations is Elekta Infinity; the company's most advanced digital linear accelerator, now available to customers in the United States. Elekta Infinity increases speed and precision in delivering Volumetric Modulated Arc Therapy (VMAT), offering patients shortened treatment times with the highest degree of precision.

"Elekta Infinity is redefining conformity and speed of treatment providing physicians with a mechanism to apply their skills to deliver the best possible care to patients," says Tomas Puusepp, President and CEO of Elekta. "The simplicity and flexibility of use of Elekta Infinity allows it to be the leading edge treatment tool in large university settings as well as the department mainstay in community hospital settings. It truly provides the best for both worlds."

In addition to the company's presence at ASTRO, a full product preview will be provided to Elekta customers at the 17th Annual Radiation Oncology Users' Meeting. Expected to draw more than 1,500 attendees, the meeting will focus on optimizing clinical efficiency using Elekta's latest advancements in radiation treatment planning (RTP), VMAT planning and delivery and image-integrated Electronic Medical Records with MOSAIQ® 2.0.

Customers attending the Users Meeting also will be among the first to see the new face and voice of Elekta, as the company introduces its new family of brands unified under the Elekta name: Elekta Oncology, Impac Software, CMS Software and Leksell Stereotaxy.

"Everyone attending ASTRO will see how our family of companies has redefined the boundaries of science and technology to assist clinicians in improving and saving patients' lives," says Joseph K. Jachinowski, President and CEO of Elekta North America. "We want our customers to be the first to know that the Elekta Group is moving forward with a shared vision to deliver clinical advances for improved patient outcomes. We believe that human care makes the future possible."

Other Meeting Highlights

At the 50th Annual ASTRO meeting, Elekta will announce product innovations to improve the planning, workflow management and delivery of radiation therapy, including:

- MOSAIQ® 2.0, a comprehensive oncology charting solution that tracks patients from the moment they enter the cancer center through long-term follow-up. MOSAIQ 2.0 increases process efficiency and facilitates high-quality patient care.

- Monaco*™ VMAT Planning, the next-generation Intensity Modulated Radiotherapy (IMRT) treatment planning system featuring biological modeling, constrained optimization, and Monte Carlo dose calculation algorithms, representing a fundamentally new approach to IMRT.

- Atlas-Based Autosegmentation (ABAS), a software application that produces an estimate of the anatomy boundary contours needed to create a radiation treatment plan. The stand-alone, vendor-neutral product significantly reduces the amount of time spent creating and editing patient contours.

- Extend*™ Program, a complete system for extending the utilization of Leksell Gamma Knife® Perfexion™ enabling clinicians to treat indications previously untreatable with Gamma Knife surgery. The rigid carbon-fiber construction of the Extend frame provides maximum stability, enabling the most accurate, non-invasive localization available.

For additional information, visit http://www.elekta.com/ewavelength or http://www.elekta.com/evc.

Events Held in Conjunction with ASTRO

Elekta also is hosting the following educational seminars and events:

- Saturday, September 20, 17th Annual Radiation Oncology Users Meeting, 9 a.m. - 4 p.m., Boston's Wang Theater, 270 Tremont Street
- Saturday, September 20, Annual Radiation Oncology Users Party, 7:30 -11 p.m., Roxy Theater, 279 Tremont Street
- Monday, September 22, Investor's Meeting, 2 - 4 p.m., Renaissance Boston Waterfront Hotel, Pacific Salon, 606 Congress Street
- Tuesday, September 23, Media Roundtable Event: Paradigms in Radiation Medicine, 3:30 - 5 p.m., Boston Renaissance Waterfront, Thompson Room, 606 Congress Street

*Extend™ and Monaco™ VMAT each require 510(k) review and are not yet commercially available in the U.S.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit http://www.elekta.com.

This information was brought to you by Cision http://www.cisionwire.com

Elekta




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Urology
ADHD Autism Diabetes

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
Shocking Pictures To Appear On Cigarette Packets In UK On 1st October
27 Sep 2008
The UK's ten million Smokers may see pictures of rotting teeth, throat cancer, and indications of male impotence (erectile dysfunction) on cigarette packets they buy at the beginning of October...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...